This Article Full Text Full Text (PDF) Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Blayney, D. W. Search for Related Content PubMed Articles by Blayney, D. W. Social Bookmarking                            What's this?

From Bench to Benchmarking

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

Douglas W. Blayney, MD

Would it surprise you to know that the first patients with Hodgkin's disease treated with MOPP (mustargen, vincristine, prednisone, procarbazine) were continually hospitalized in the National Cancer Institute Clinical Center for 6 months? MOPP is widely regarded as the first curative chemotherapy for a previously incurable adult malignancy. The regimen also served as the prototype for development of the cyclic cytotoxic chemotherapy regimens in use today, and for decades was a benchmark for the treatment of Hodgkin's disease. Thirty-three years later, MOPP's successor chemotherapies are infused in oncologist offices, and patients then recover in their own . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?